We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

595 hedge funds and large institutions have $30B invested in Alexion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 218 increasing their positions, 214 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 45

27% more call options, than puts

Call options by funds: $551M | Put options by funds: $435M

15% more capital invested

Capital invested by funds: $26B → $30B (+$4.01B)

6% more funds holding

Funds holding: 559 → 595 (+36)

2% more repeat investments, than reductions

Existing positions increased: 218 | Existing positions reduced: 214

0% more funds holding in top 10

Funds holding in top 10: 19 → 19 (0)

Holders
595
Holders Change
+36
Holders Change %
+6.44%
% of All Funds
14.83%
Holding in Top 10
19
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.47%
New
88
Increased
218
Reduced
214
Closed
45
Calls
$551M
Puts
$435M
Net Calls
+$117M
Net Calls Change
-$98.3M

Top Buyers

1
Jennison Associates
Jennison Associates
New York
+$636M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$118M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$83.6M
4
UBS AM
UBS AM
Illinois
+$69.1M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$67.9M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$328M
2
Sands Capital Management
Sands Capital Management
Virginia
-$213M
3
Goldman Sachs
Goldman Sachs
New York
-$183M
4
State Street
State Street
Massachusetts
-$82.3M
5
BlackRock
BlackRock
New York
-$77.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
601
Sphera Funds Management
Israel
– -$12.2M -100,000 Closed
SC
602
Samlyn Capital
New York
– -$10.2M -84,100 Closed
FHAM
603
Folger Hill Asset Management
New York
– -$9.13M -75,019 Closed
Fidelity International
604
Fidelity International
Bermuda
– -$8.72M -71,693 Closed
SGA
605
Sector Gamma AS
Norway
– -$4.9M -40,300 Closed
Walleye Trading
606
Walleye Trading
New York
– -$2.99M -22,031 Closed
PCM
607
Proxima Capital Management
New York
– -$1.82M -15,000 Closed
PCM
608
Prelude Capital Management
New York
– -$1.52M -12,470 Closed
ACM
609
Asymmetry Capital Management
California
– -$1.49M -12,210 Closed
JGGDR
610
JGP Global Gestao de Recursos
Brazil
– -$1.31M -10,743 Closed
QAM
611
Quantres Asset Management
Cayman Islands
– -$1.16M -9,500 Closed
SDIC
612
South Dakota Investment Council
South Dakota
– -$1.12M -9,200 Closed
JCM
613
Jafra Capital Management
New York
– -$1.07M -8,826 Closed
Simplex Trading
614
Simplex Trading
Illinois
– -$942K -6,937 Closed
SI
615
Stephens Inc
Arkansas
– -$813K -6,683 Closed
RCAMU
616
Rothschild & Co Asset Management US
Connecticut
– -$647K -5,319 Closed
EMG
617
Ellington Management Group
Connecticut
– -$608K -5,000 Closed
HP
618
Hikari Power
Japan
– -$608K -5,000 Closed
RGI
619
River Global Investors
United Kingdom
– -$464K -3,810 Closed
AF
620
Aldebaran Financial
– -$426K -3,500 Closed
CCIA
621
Campbell & Co Investment Adviser
Maryland
– -$407K -3,348 Closed
TSS
622
Two Sigma Securities
New York
– -$406K -3,334 Closed
LP
623
LMR Partners
United Kingdom
– -$379K -3,119 Closed
WC
624
Wexford Capital
Florida
– -$353K -2,900 Closed
TRCT
625
Tower Research Capital (TRC)
New York
– -$218K -1,793 Closed
22 23 24
25
26

ALXN Hedge Fund Activity: Q3 2017 in Review

595 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2017, worth a combined $30B — up 15% from $26B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ALXN positions and 45 closed out — a net gain of 43 holders — while 218 added to existing stakes and 214 trimmed.

The largest buyer was Jennison Associates, adding an estimated $636M. The largest seller was Fidelity Investments, cutting an estimated $328M.

  • 595 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2017, up from 559 in Q2 2017.
  • Funds reported $30B of Alexion Pharmaceuticals stock for Q3 2017, up 15% quarter-over-quarter.
  • 88 funds opened new Alexion Pharmaceuticals positions in Q3 2017 and 45 closed out, a net change of +43 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2017 was Jennison Associates, an estimated $636M added.
  • The largest Alexion Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $328M sold.

Based on aggregated 13F filings for Q3 2017.